ストックスクリーナーアプリを入手
12.77
3.04%
-0.40
前日終値:
$13.17
開ける：
$13.12
24時間の取引高:
1.84M
Relative Volume:
0.90
時価総額：
$1.64B
収益：
-
当期純損益:
$-29.07M
株価収益率:
-44.03
EPS:
-0.29
ネットキャッシュフロー:
$-31.85M
1週間 パフォーマンス:
-5.20%
1か月 パフォーマンス:
+7.76%
6か月 パフォーマンス:
+106.97%
1年 パフォーマンス:
+254.72%
1日の値動き範囲:
$12.71
$13.45
1週間の範囲:
$12.71
$14.39
52週間の値動き範囲:
$3.4715
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
名前
Trevi Therapeutics Inc
セクター
電話
203-304-2499
住所
195 CHURCH STREET, NEW HAVEN, CT
TRVI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
12.77 | 1.69B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-08-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-07-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 繰り返されました | Needham | Buy |
| 2025-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-30 | 開始されました | Raymond James | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-12 | 開始されました | B. Riley Securities | Buy |
| 2022-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | BMO Capital Markets | Outperform |
| 2019-06-03 | 開始されました | Needham | Buy |
| 2019-06-03 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | Stifel | Buy |
すべてを表示
Trevi Therapeutics Inc (TRVI) 最新ニュース
Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria
Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat
226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat
Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail
Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria
Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com
Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com
New Haven biotech names new CFO - Hartford Business Journal
Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat
Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria
Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma
Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat
Trevi Therapeutics Names David Hastings CFO - marketscreener.com
Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com
Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - cnhinews.com
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
Trevi Therapeutics stock hits all-time high at 13.92 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits all-time high at 13.92 USD - Investing.com
Trevi Therapeutics (TRVI) Rises on Takeover Speculation - GuruFocus
Trevi Therapeutics edges higher amid takeover speculation - MSN
Trevi Therapeutics edges higher amid takeover speculation (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics (TRVI) Stock Analysis Report | Financials & Insights - Benzinga
Jefferies Financial Group Inc. Makes New Investment in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Tejara Capital Ltd Purchases 146,879 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week HighStill a Buy? - MarketBeat
Stocks of Trevi Therapeutics Inc (TRVI) are poised to climb above their peers - Setenews
Trevi Therapeutics stock hits all-time high at 12.31 USD By Investing.com - Investing.com India
Trevi Therapeutics stock hits all-time high at 12.31 USD - Investing.com
AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration - simplywall.st
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight - GlobeNewswire Inc.
MAI Capital Management Sells 537,497 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat
B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat
B. Riley Predicts Increased Earnings for Trevi Therapeutics - Defense World
Trevi Therapeutics Inc (TRVI) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):